Jessica Stitt
Nessuna posizione attualmente
Profilo
Jessica Stitt served as Vice President of Finance and Operations at MyoKardia, Inc. from 2020 to 2021.
Prior to that, she was Vice President of Finance and Investor Relations at Theravance Biopharma, Inc. She then served as Chief Financial Officer at Gyroscope Therapeutics Holdings Plc from 2021 to 2022.
Stitt received her undergraduate degree from St. Anselm College and her MBA from Simmons School of Management.
Precedenti posizioni note di Jessica Stitt
| Società | Posizione | Fine |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Director of Finance/CFO | 01/04/2022 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 01/01/2021 |
| THERAVANCE BIOPHARMA, INC. | Public Communications Contact | - |
Formazione di Jessica Stitt
| St. Anselm College | Undergraduate Degree |
| Simmons School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| THERAVANCE BIOPHARMA, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Jessica Stitt
